Pfizer news
FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For Treatment Of Pulmonary Arterial Hypertension
FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For Treatment Of Pulmonary Arterial Hypertension
Reuters Key Development - 35 minutes ago
Pfizer Executive:In Talks To Expand Licensing Pact With Aurobindo
Submitted by on Fri, 11/20/2009 - 14:04Pfizer Executive:In Talks To Expand Licensing Pact With Aurobindo
Wall Street Journal - 1 hour ago
HYDERABAD (Dow Jones)--Pfizer Inc. (PFE) is looking to expand its licensing pact with Aurobindo Pharma Ltd. (524804.BY) to add more products and markets, a senior company executive said Friday ...
- Login or register to post comments
- 20 reads
- Feed: News for Pfizer Inc. - Google Finance
- Feed: Aurobindo Pharma News
- Original article
Trading Review for Vivus Inc. Issued by Beacon Equity
Trading Review for Vivus Inc. Issued by Beacon Equity
Trading Markets - 13 minutes ago
DALLAS, Nov 20, 2009 (GlobeNewswire via COMTEX) -- VVUS -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Vivus Inc. (Nasdaq:VVUS). The report includes ...
Pfizer Announces FDA Advisory Committee Finds Data Support Claim That SPIRIVA HandiHaler Reduces COPD Exacerbations
Pfizer Announces FDA Advisory Committee Finds Data Support Claim That SPIRIVA HandiHaler Reduces COPD Exacerbations
Reuters Key Development - 1 hour ago
Prescription for opportunity
Prescription for opportunity
Lower Hudson Journal news - 30 minutes ago
Considering the cold shoulder New York gives to business, even in this economic climate, locals should, and did, cheer Pfizer Inc.'s announcement that the Pearl River campus will be one of just ...
Monsanto Buying Pfizer Research Campus
Monsanto Buying Pfizer Research Campus
St. Louis Chinese American News - 48 minutes ago
Twenty-five years ago, fast-growing Monsanto Co. christened a new research campus in Chesterfield. On Monday, a reincarnation of the same company reclaimed the property for $435 million. Monsanto ...
Goldman Sachs Puts Pfizer's 2012 China Sales At $$3 Billion
Goldman Sachs Puts Pfizer's 2012 China Sales At $$3 Billion
istockAnalyst.com - 47 minutes ago
In an investment review of Pfizer (NYSE: PFE ), Goldman Sachs said sales in emerging growth markets would become a significant factor in the company's revenues, a fact that it considers ...
